Is metastatic pancreatic cancer an untargetable malignancy?

doi:10.4251/wjgo.v8.i3.297

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (10152)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-3) series.

Item

Count

PDF

541

WORD

271

HTML

4055

Tables (1-3)

232

Sum=5099

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

485

Download

1330

Sum=1815

Publishing Process of This Article

Item

Count

Browse

1290

Download

1948

Sum=3238

Mar 15, 2016 (publication date) through Jan 2, 2025

Times Cited of This Article

Times Cited (8)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastrointest Oncol. Mar 15, 2016; 8(3): 297-304
Published online Mar 15, 2016. doi: 10.4251/wjgo.v8.i3.297

Table 3 New treatment modalities based on targeted therapies in metastatic pancreatic cancer

Treatment modality	Mechanism of action	Target
Immunotherapy	Check point inhibitors	CTLA4
Immunotherapy	Adoptive cell therapy	T-cells
Epigenetics	Histone acetylation	Histones
Stromal extracellular matrix	Hyaluronidase	Hyaluronan
Tumor suppressor genes regulation	miRNA inhibitors	TP53-SMAD4- CDKN2A
Tumor suppressor genes regulation	Anti-PARP	BRCA1-BRCA2

CTLA4: Cytotoxic T-lymphocyte-associated antigen 4; TP53-SMAD4- CDKN2A: Tumor protein p53 - cyclin-dependent kinase inhibitor 2A; BRCA: Breast cancer; PARP: PolyADP ribose polymerase.

Citation: Kourie HR, Gharios J, Elkarak F, Antoun J, Ghosn M. Is metastatic pancreatic cancer an untargetable malignancy? World J Gastrointest Oncol 2016; 8(3): 297-304
URL: https://www.wjgnet.com/1948-5204/full/v8/i3/297.htm
DOI: https://dx.doi.org/10.4251/wjgo.v8.i3.297